Clinical Trials at Massachusetts General Hospital Cancer Center
As of July 2026, 59 paid clinical trials are recruiting at Massachusetts General Hospital Cancer Center, located at 55 FRUIT ST, CARDIOLOGY, GRB 800, MS 843, BOSTON, MA 02114-2621, phone (617) 724-1935 in Boston, Massachusetts. Active studies at this site cover conditions such as Breast Cancer, Prostate Cancer and Heart Failure. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
59 clinical trials at Massachusetts General Hospital Cancer Center
·Clear filters·↓ Download CSVONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
Project: Every Child for Younger Patients With Cancer
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
BILe Acid-gut Microbiome Axis MODification Through Diet Education for Colorectal Cancer Prevention
Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
IVIG for Infection Prevention After CAR-T-Cell Therapy
About research studies in Boston
Boston has approximately 3,030 recruiting research studies across a wide range of therapeutic areas. Massachusetts is a global epicenter of biomedical research, anchored by Harvard-affiliated hospitals (MGH, Brigham and Women's, Dana-Farber), Boston Children's Hospital, and the Kendall Square biotech corridor in Cambridge.
Common conditions studied in Boston
- Breast Cancer (65 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Prostate Cancer (44 active studies). Prostate cancer studies test next-generation hormone therapies, PARP inhibitors, and radioligand treatments for both localized and advanced disease.
- Heart Failure (36 active studies). Heart failure trials explore SGLT-2 inhibitors, novel myosin modulators, and device-based therapies for both reduced and preserved ejection fraction.
- Ovarian Cancer (36 active studies). Ovarian cancer research examines PARP inhibitors, maintenance therapies, and antibody-drug conjugates for recurrent and platinum-resistant disease.
- Acute Myeloid Leukemia (34 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
- Advanced Solid Tumor (33 active studies). Recruiting Advanced Solid Tumor studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
Leading research sponsors in Boston
- Massachusetts General Hospital
- Brigham and Women's Hospital
- Boston Children's Hospital
- Dana-Farber Cancer Institute
- Beth Israel Deaconess Medical Center
Local regulations and guidelines
Clinical trials in Massachusetts are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Massachusetts trials follow additional state privacy requirements enforced under 201 CMR 17.00 and oversight from the Massachusetts Department of Public Health.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Boston. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Boston
Hipa.ai aggregates every recruiting study in Boston from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Boston?
There are approximately 3,030 recruiting clinical trials in Boston, Massachusetts listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Boston pay participants?
Most recruiting trials in Boston compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Boston?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Boston?
The most common conditions under active study in Boston include Breast Cancer (65), Prostate Cancer (44), Heart Failure (36), Ovarian Cancer (36), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Boston?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Boston on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Boston?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Boston?
Recruiting research sites in Boston include Massachusetts General Hospital, Brigham and Women's Hospital, Dana-Farber Cancer Institute, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Boston right now?
The largest active categories in Boston are Cancer & tumors (933), Neurology & pain (227), Cardiovascular (188). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Massachusetts General Hospital Cancer Center?
Massachusetts General Hospital Cancer Center is located at 55 FRUIT ST, CARDIOLOGY, GRB 800, MS 843, BOSTON, MA 02114-2621. Use the Google Maps link in the intro above to get directions.
How do I contact Massachusetts General Hospital Cancer Center?
You can reach Massachusetts General Hospital Cancer Center by phone at (617) 724-1935. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.